Article in Hepatology communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 3 pooled it
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it, 10 citations in OpenAlex.
Johan L K Van HoveSection of Clinical Genetics and Metabolism, Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus and Children's Hospital Colorado, Aurora, Colorado, USA.ORCID 0000-0003-2850-3294
Marisa W FriederichSection of Clinical Genetics and Metabolism, Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus and Children's Hospital Colorado, Aurora, Colorado, USA.ORCID 0000-0003-0902-5565
Dana K StrodeSection of Clinical Genetics and Metabolism, Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus and Children's Hospital Colorado, Aurora, Colorado, USA.ORCID 0000-0002-7198-7939
Roxanne A Van HoveSection of Clinical Genetics and Metabolism, Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus and Children's Hospital Colorado, Aurora, Colorado, USA.ORCID 0000-0002-4997-2615
Kristen R MillerSection of Endocrinology, Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus and Children's Hospital Colorado, Aurora, Colorado, USA.ORCID 0000-0002-3675-2533
Rohit SharmaDepartment of Molecular Biology and Department of Medicine, Howard Hughes Medical Institute, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-1847-682
Hardik ShahDepartment of Molecular Biology and Department of Medicine, Howard Hughes Medical Institute, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0001-8408-5686
Jane EstrellaSection of Clinical Genetics and Metabolism, Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus and Children's Hospital Colorado, Aurora, Colorado, USA.ORCID 0000-0001-5995-6195
Linda GabelDepartment of Pathology and Laboratory Medicine, Children's Hospital Colorado, Aurora, Colorado, USA.ORCID 0000-0003-4783-8006
Simon HorslenDepartment of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-5949-7363
Rohit KohliDivision of Gastroenterology, Hepatology, and Nutrition, Children's Hospital Los Angeles, Los Angeles, California, USA.ORCID 0000-0002-0198-7703
Mark A LovellDepartment of Pathology and Laboratory Medicine, Children's Hospital Colorado, Aurora, Colorado, USA.ORCID 0000-0001-6423-1498
Alexander G MiethkeDepartment of Pediatrics, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.ORCID 0000-0003-1395-9475
Jean P MollestonDivision of Pediatric Gastroenterology, Hepatology and Nutrition, Indiana University and Riley Hospital for Children, Indianapolis, Indiana, USA.ORCID 0000-0002-8708-0298
Rene RomeroDivision of Pediatric Gastroenterology, Hepatology and Nutrition, Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, Georgia, USA.ORCID 0000-0002-1566-2280
James E SquiresDepartment of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-6979-8987
Estella M AlonsoDepartment of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois, USA.ORCID 0000-0002-4056-7752
Stephen L GutheryDepartment of Pediatrics, Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Spencer F. Eccles School of Medicine, University of Utah, Salt Lake City, Utah, USA.ORCID 0000-0003-1484-301
Binita M KamathDivision of Gastroenterology, Hepatology and Nutrition, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0002-9982-5023
Kathleen M LoomesDivision of Gastroenterology, Hepatology and Nutrition, The Children's Hospital Philadelphia, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-1539-6672
Philip RosenthalDepartments of Pediatrics and Surgery, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0001-7840-5401
Krupa R MysoreDepartment of Pediatrics, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas, USA.ORCID 0000-0001-9890-5518
Laurel A CavalloDepartment of Pediatrics, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas, USA.ORCID 0000-0002-8531-840
Pamela L ValentinoDivision of Gastroenterology and Hepatology, Seattle Children's Hospital, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-8227-2004
John C MageeDepartment of Surgery, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0001-8416-7905
Shikha S SundaramSection of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus and Children's Hospital Colorado, Aurora, Colorado, USA.ORCID 0000-0003-2523-6389
Ronald J SokolSection of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus and Children's Hospital Colorado, Aurora, Colorado, USA.ORCID 0000-0001-7433-4095
Childhood Liver Disease Research Network (ChiLDReN)
Children's Hospital Colorado · USChildren's Hospital of Pittsburgh · USTexas Children's Hospital · USBroad Institute · USChildren's Healthcare of Atlanta · USChildren's Hospital of Los Angeles · USChildren's Hospital of Philadelphia · USCincinnati Children's Hospital Medical Center · USHoward Hughes Medical Institute · USLurie Children's Hospital · USPrimary Children's Hospital · USRiley Hospital for Children · USSeattle Children's Hospital · USUniversity of California San Diego · USUniversity of California, San Francisco · USUniversity of Michigan · USUniversity of Toronto · CA
Funding
Phenotypic Diversity in COVID-19UL1TR001878 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2016 to 2025
$102.4M
PILOT STUDY--SUBSTRATE METABOLISM IN EXTREMELY LOW BIRTH WEIGHT INFANTSP30DK048520 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI BRYAN C BERGMAN · 1995 to 2026
$32.6M
Colorado Clinical and Translational Sciences Institute (CCTSI)UM1TR004399 · NCATS · UNIVERSITY OF COLORADO DENVER · PI JANINE A HIGGINS, RONALD J. SOKOL · 2023 to 2026
$30.7M
Stem Cell/Organoid and Genome Editing CoreP30DK078392 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI LEE ARMISTEAD DENSON · 2007 to 2026
$24.4M
Childhood Liver Disease Research Network Data Coordinating CenterU24DK062456 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI JOHN C MAGEE · 2019 to 2026
$18.9M
The North American Mitochondrial Disease Consortium (NAMDC)U54NS078059 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HAAS, RICHARD H · 2011 to 2023
$17.5M
Etiology and Treatment of Biliary Atresia and INHU01DK062453 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI RONALD J. SOKOL · 2002 to 2026
$13.5M
Clinical Center for Cholestatic Liver Disease in ChildrenU01DK062497 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI Alexander Miethke · 2002 to 2026
$13.2M
VCU-Atlanta Center for the Childhood Liver Disease Research Network (ChiLDReN)U01DK062470 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI SAUL J. KARPEN · 2005 to 2026
$12.7M
Mid-Atlantic BANH Consortium SiteU01DK062481 · NIDDK · CHILDREN'S HOSP OF PHILADELPHIA · PI Binita Maya Kamath, Kathleen Mary Loomes · 2002 to 2026
$9.2M
Macrophage Cell Subset Specific Biomarkers for Disease Prognosis in Biliary AtresiaU01DK062436 · NIDDK · LURIE CHILDREN'S HOSPITAL OF CHICAGO · PI ALONSO, ESTELLA M. · 2002 to 2023
$7.0M
The Pittsburgh Cholestatic Liver Disease ConsortiumU01DK062466 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HORSLEN, SIMON · 2002 to 2023
backgroundMitochondrial hepatopathies (MHs) are primary mitochondrial genetic disorders that can present as childhood liver disease. No recognized biomarkers discriminate MH from other childhood liver diseases. The protein biomarkers growth differentiation factor 15 (GDF15) and fibroblast growth factor 21 (FGF21) differentiate mitochondrial myopathies from other myopathies. We evaluated these biomarkers to determine if they discriminate MH from other liver diseases in children.
methodsSerum biomarkers were measured in 36 children with MH (17 had a genetic diagnosis); 38 each with biliary atresia, α1-antitrypsin deficiency, and Alagille syndrome; 20 with NASH; and 186 controls.
resultsGDF15 levels compared to controls were mildly elevated in patients with α1-antitrypsin deficiency, Alagille syndrome, and biliary atresia-young subgroup, but markedly elevated in MH (p<0.001). FGF21 levels were mildly elevated in NASH and markedly elevated in MH (p<0.001). Both biomarkers were higher in patients with MH with a known genetic cause but were similar in acute and chronic presentations. Both markers had a strong performance to identify MH with a molecular diagnosis with the AUC for GDF15 0.93±0.04 and for FGF21 0.90±0.06. Simultaneous elevation of both markers >98th percentile of controls identified genetically confirmed MH with a sensitivity of 88% and specificity of 96%. In MH, independent predictors of survival without requiring liver transplantation were international normalized ratio and either GDF15 or FGF21 levels, with levels <2000 ng/L predicting survival without liver transplantation (p<0.01).
conclusionsGDF15 and FGF21 are significantly higher in children with MH compared to other childhood liver diseases and controls and, when combined, were predictive of MH and had prognostic implications.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.